Back in 2018 Sweden's government-run AP7 pension fund acquired shares of Aurora and Canopy Growth, according to Swedish business magazine Affärsvärlden. The initial investment by the fund was 63 million Swedish kronor (~6.8M USD), with the valuation since then soaring to 100 million Swedish kronor this spring, according to a report from Sweden's public television broadcaster, SVT News.
Why is Sweden’s government pension fund investing in pot?
There’s actually a fairly simple explanation for this. The AP7 Equity Fund invests in pretty much all stocks that are included in the MSCI ACWI Index. The only exceptions are stocks that AP7 has blacklisted for one reason or another.
The fund seeks to diversify bee creating a wide global exposure to equities with, and it makes perfect sense that the fund uses the MCSI ACWI Index to achieve this goal considering the index's holdings include more than 2,700 stocks across 11 sectors in 23 developed markets and 24 emerging markets.
Once Aurora Cannabis and Canopy Growth were added to the MSCI ACWI Index in 2018, the AP7 started buying shares of both stocks.
Cannabis companies have seen positive feedback and changing attitudes and new support that is influencing lawmakers across the country. The companies are experiencing tremendous growth as a result, including MedReleaf Corp. (OTC: MEDFF), Canopy Growth Corp. (TSX: WEED) (NYSE: CGC) and GW Pharmaceuticals (NASDAQ: GWPH).
As a result of the shifting tide, specialized companies are looking to move into the medical segment by developing formulations, extracts and supplying marijuana based on their Licensed Producer status. Among these, MYM Nutraceuticals Inc is a showcase, building towards medical application. MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF) has already announced they are developing some of the world’s largest cannabis greenhouses, as well as diversified interests in cannabis derivatives, formulations and most recently, incorporated "MYM Nutraceuticals Mexico S.A. de C.V.” to focus on import and distribution of CBD-Rich Hemp products in Mexico.
Hemp, as many realize, is now legal to produce in the United States and transport, making it a newly viable crop under the federal law passed in 2018.
"In keeping with our Strategic Plan previously outlined, we're excited to add another building block by incorporating MYM Mexico and establishing an office in Mexico," said Howard Steinberg, CEO of MYM. "The Mexican government is currently considering significant cannabis reform at a national level. MYM aims to be at the forefront of this movement by positioning the company to be a key player in the importation and distribution of CBD-rich hemp products.”
For more information on MYM Nutraceuticals, Inc. Click Here
The main plan with CBD related products is aimed at focusing on the medical industry – which some hope to achieve by capitalizing on revenue streams they control. For instance, on top of the various Greenhouses MYM is currently developing, and the vast quantities of other Cannabis related fields they are already engaged in, MYM is also engaged in the development of seed and live tissue culture, which they can sell independently through a variety of different seed banks around the world. They also have a number of large grows in Canada and abroad, which will produce flower for, and have the capability of carrying out extraction with down to oil.
MYM Nutraceuticals also have a manufacturing facility in its final stages of completion that will allow the company to produce final consumables in the forms of transdermal patches, pills, tinctures, things of that nature for humans.
Through its various joint ventures, the company is currently building three large-scale production facilities in both Canada and Australia. Upon completion of these three projects, the total amount of greenhouse growing space is expected to exceed 2.7 million square feet. MYM management states that it is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.
Other companies that stand to benefit greatly from the increased adoption of medical marijuana and the demand for supplies it creates include:
MedReleaf Corp. (OTC: MEDFF) sets The Medical Grade Standard for cannabis in Canada and around the world. The first and only ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.
Canopy Growth Inc. (TSX: WEED) (NYSE: CGC) is the world’s largest diversified cannabis company. Canopy boasts a wide offering of distinct brands and curated cannabis varieties in dried, oil and capsule forms.
GW Pharmaceuticals (NASDAQ: GWPH) successfully developed the world’s first prescription medicine derived from the cannabis plant, Sativex®, now approved in over 29 countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis.
For a more in-depth look into MYM you can view the in-depth report at USA News Group https://usanewsgroup.com/2019/04/10/the-top-unicorn-sectors-for-stock-traders-in-2019/
USA News Group
http://usanewsgroup.com
[email protected]
Legal Disclaimer/Disclosure:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for MYM Nutraceuticals advertising and digital media. There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group has purchased a total of two thousand shares of MYM Nutraceuticals in the open market and own an additional five hundred and fifty five five hundred and fifty five thousand shares purchased through a subscription agreement (along with a corresponding amount of warrants exercisable at .40 starting October 3, 2017) and have no plans on selling these shares in the next 72 hours (from June 19, 2017) but reserve the right to buy and sell shares in MYM Nutraceuticals, Inc. at any point after June 22, 2017 – No further notice shall be given. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
